Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00086944 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions

BIOLOGICAL: oblimersen sodium
BIOLOGICAL: rituximab
DRUG: ifosfamide
DRUG: carboplatin
DRUG: etoposide
BIOLOGICAL: filgrastim
BIOLOGICAL: pegfilgrastim
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)